Atrial Septal Defect (ASD) Closure: Transcatheter and Surgical Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

An atrial septal defect (ASD) is a persistent congenital communication between the left and right atria, accounting for approximately 10% of all congenital heart defects and representing one of the most frequently encountered structural cardiac abnormalities in adult cardiology. Persistent left-to-right shunting causes progressive right atrial and right ventricular volume overload, pulmonary overcirculation, atrial arrhythmias, paradoxical embolism, and — if uncorrected — irreversible pulmonary arterial hypertension (Eisenmenger physiology).

Four anatomically distinct subtypes are recognised. Ostium secundum ASD (approximately 75% of cases) occupies the central fossa ovalis and is the type most amenable to percutaneous transcatheter device closure. Ostium primum ASD (15–20%) lies inferiorly adjacent to the AV valves, is associated with AV canal defects and Down syndrome, and invariably requires open surgical repair. Sinus venosus ASD (5–10%) is located posterosuperiorly near the superior vena cava and is almost universally associated with partial anomalous pulmonary venous connection (PAPVC), mandating surgery. Coronary sinus ASD (unroofed coronary sinus, <1%) is rare and requires surgical reconstruction.

The haemodynamic threshold for intervention is a pulmonary-to-systemic flow ratio (Qp:Qs) greater than 1.5:1, accompanied by right heart enlargement on echocardiography. Closure is also indicated for paradoxical embolism, cryptogenic stroke with a high-risk patent foramen ovale (PFO), or significant symptoms refractory to medical management.

Percutaneous transcatheter closure has become the standard of care for suitable ostium secundum defects, guided by transesophageal (TEE) or intracardiac echocardiography (ICE). The Amplatzer Septal Occluder (ASO) achieves complete closure in over 96% of cases at 3 years with a hospital stay of only 24–48 hours, avoiding the morbidity of sternotomy and cardiopulmonary bypass.

ASD closure — transcatheter or surgical — addresses distinct structural defects and related clinical scenarios:

• Ostium secundum ASD with haemodynamically significant shunt (Qp:Qs >1.5:1): The primary indication. Device closure is preferred for defects with stretched diameter ≤40 mm and adequate septal rims ≥5 mm; a deficient aortic rim is acceptable as the aorta provides structural support for the device disc.
• Ostium primum ASD: Requires open surgical repair with autologous pericardial or Dacron patch and cleft mitral valve repair to address associated mitral regurgitation.
• Sinus venosus ASD with PAPVC: Surgical baffle repair redirecting anomalous pulmonary veins to the left atrium; the Warden procedure (SVC translocation above the anomalous vein insertion) is preferred at high-volume centres.
• Patent foramen ovale (PFO) with cryptogenic ischaemic stroke: In patients under 60 years with high-risk PFO anatomy (diameter ≥2 mm or associated atrial septal aneurysm), transcatheter closure reduces recurrent stroke risk by 50–70% compared with antithrombotic therapy alone, demonstrated by the CLOSE (2017), GORE-REDUCE (2017), and RESPECT Extended (2017) randomised controlled trials.
• ASD with early pulmonary arterial hypertension: Closure is feasible when pulmonary vascular resistance (PVR) is <8 Wood units and left-to-right shunting persists. Fenestrated device closure may be considered in borderline haemodynamics.
• ASD with atrial arrhythmias or paradoxical embolism: Structural correction reduces — though does not eliminate — arrhythmia burden and embolic risk, particularly when closure is performed before the age of 40.
• Large ASD with right heart failure: Closure combined with diuretic optimisation and, when indicated, pulmonary vasodilator therapy in patients with borderline PVR.

Patient selection integrates anatomical, haemodynamic, and clinical parameters assessed by a multidisciplinary congenital heart disease team.

Eligible for transcatheter device closure when all criteria are met:

• Ostium secundum morphology confirmed by TEE or cardiac MRI
• Stretched defect diameter ≤40 mm (device chosen at 1–2 mm above stretched diameter)
• Adequate septal rims ≥5 mm in all directions; deficient aortic rim is acceptable
• No proximity to AV valves, coronary sinus orifice, or pulmonary vein ostia
• Haemodynamically significant shunt: Qp:Qs >1.5:1 and/or right heart enlargement on imaging
• Pulmonary vascular resistance <8 Wood units (net left-to-right shunt confirmed)

Surgical repair required when:

• Primum, sinus venosus, or coronary sinus ASD morphology
• Secundum ASD with stretched diameter >40 mm or inadequate rims
• Associated anomalies requiring open correction (PAPVC, cleft mitral valve, inlet VSD)
• Previous failed or complicated device closure

Absolute contraindications to closure:

• Severe irreversible PAH with net right-to-left shunting (Eisenmenger syndrome) — closure is harmful and contraindicated
• Active infective endocarditis or uncontrolled systemic infection
• Intracardiac thrombus without adequate anticoagulation
• Severe left ventricular dysfunction without reversible aetiology

Pre-procedure workup: TTE and TEE are mandatory. Cardiac CT angiography excludes anomalous vessels and assesses aortic proximity. Right heart catheterisation with vasoreactivity testing is performed when PVR elevation is suspected. Neurology review is arranged for PFO-cryptogenic stroke candidates, with imaging to confirm embolic infarct pattern and exclude alternate causes.

1. Percutaneous Transcatheter Device Closure

Performed under general anaesthesia or conscious sedation in a cardiac catheterisation laboratory with fluoroscopic and echocardiographic (TEE or ICE) guidance. Femoral venous access is obtained; a sizing balloon calibrates the stretched defect diameter. The device — typically 1–2 mm larger than stretched diameter — is deployed under real-time imaging.

Approved devices:

• Amplatzer Septal Occluder (ASO) — Abbott Medical: Self-expanding nitinol double-disc device, sizes 4–40 mm. The Dacron mesh fabric promotes thrombus organisation and endothelialisation, achieving complete closure in >96% by 3 years. The global reference standard with the largest evidence base.
• GORE CARDIOFORM ASD Occluder: Flexible ePTFE membrane on a nitinol frame; preferred for deficient aortic rims due to its highly conformable design and lower erosion profile.
• Occlutech Figulla Flex II: Single-wire nitinol construct with a flexible waist and minimal left atrial disc protrusion; widely used in Europe and Asia.
• Lifetech CERA / CeraFlex: Ceramic-coated nitinol; popular in Asia and Latin America.

For PFO closure specifically, the GORE CARDIOFORM Septal Occluder, Amplatzer PFO Occluder, and Occlutech PFO Occluder are the regulatory-approved options in respective markets.

2. Open Surgical Repair

Performed with cardiopulmonary bypass via median sternotomy, right anterolateral mini-thoracotomy, or — at specialist centres — robotic-assisted endoscopic approach. Small secundum defects (<2 cm) are closed by primary suture; larger defects use autologous pericardial or synthetic (Dacron/PTFE) patch. Primum ASDs require inferior septal patch plus cleft mitral leaflet repair. Sinus venosus defects use a pericardial baffle or the Warden procedure (SVC translocation above the anomalous pulmonary vein insertion). Minimally invasive right mini-thoracotomy achieves equivalent haemodynamic outcomes with superior cosmesis and shorter inpatient stay.

3. Hybrid Approaches

In young children or patients with complex anatomy, a hybrid approach — surgical exposure combined with transcatheter device deployment under direct vision — avoids cardiopulmonary bypass while ensuring anatomically precise closure.

Timely ASD closure provides substantial, durable haemodynamic, symptomatic, and prognostic benefits:

Haemodynamic correction: Closure eliminates the left-to-right shunt, resulting in progressive regression of right atrial and right ventricular dilatation. Right ventricular end-diastolic volume and tricuspid annular diameter normalise in the majority of patients within 12 months, reducing the substrate for arrhythmia and tricuspid regurgitation.

Symptom relief: Exertional dyspnoea, fatigue, and exercise intolerance resolve markedly. Peak oxygen consumption (VO₂) increases significantly within 6–12 months post-closure; most patients achieve NYHA functional class I–II.

Advantages of transcatheter approach over open surgery: No sternotomy or cardiopulmonary bypass, reducing procedural morbidity dramatically. Hospital stay is 24–48 hours versus 5–7 days for open repair. Return to full activity occurs in 2–4 weeks rather than 6–8 weeks. Cosmesis is excellent — femoral venous access only, no chest scar.

Stroke prevention — PFO closure: The CLOSE trial demonstrated a 97% relative risk reduction in recurrent stroke at 5-year follow-up in patients under 60 with PFO plus atrial septal aneurysm randomised to device closure versus antithrombotic therapy. The RESPECT Extended trial confirmed sustained benefit at 5.9 years: 3.8 events/1,000 patient-years (device) vs 5.8 events/1,000 patient-years (medical therapy).

Arrhythmia prevention: Closure before age 40 significantly reduces the lifetime risk of atrial fibrillation and flutter by eliminating right atrial volume overload. Patients already in AF may benefit from concurrent surgical cryoablation at the time of open repair.

PAH stabilisation and prevention: In patients with early PAH, successful closure stabilises or partially reverses pulmonary vascular disease in the majority, provided PVR is still <8 Wood units at the time of intervention. Closure after development of irreversible Eisenmenger physiology is contraindicated.

ASD closure carries well-characterised risks that differ between transcatheter and surgical approaches.

Transcatheter device closure risks:

• Device erosion/cardiac perforation (<0.1%): The most feared late complication — device erosion into the aortic root or atrial roof causing haemopericardium. Risk is highest with oversized devices and severely deficient aortic rims. The FDA IMPACT Registry reports erosion in approximately 0.04% of implants. Surveillance echocardiography is mandatory.
• Residual shunt (3–10% early): Most close spontaneously by 6 months as the device fabric endothelialises. Persistent moderate-to-large residual shunts may require re-intervention.
• Device embolisation (<1%): Typically within 24 hours; transcatheter retrieval is feasible in most cases. Surgical retrieval is rarely required.
• Device thrombus (<1%): Risk is highest in the first 6 months pre-endothelialisation; mitigated by dual antiplatelet therapy.
• Cardiac tamponade (<0.5%): From transeptal puncture or device-related perforation; urgent pericardiocentesis is required.
• Air or thrombus embolism: Meticulous de-airing and anticoagulation protocols mitigate this procedural risk.

Surgical repair risks:

• Complete AV block (<1%): Risk after primum ASD repair near the AV node; may require permanent pacemaker implantation.
• Post-pericardiotomy syndrome (5–10%): Pericardial inflammation 1–6 weeks post-surgery; managed with NSAIDs and colchicine for recurrent episodes.
• Early post-operative atrial fibrillation: Common in adults over 40; typically self-limiting but may require pharmacological or electrical cardioversion.
• CPB-related morbidity: Systemic inflammatory response, transfusion requirements, and transient neurocognitive effects in elderly patients undergoing prolonged bypass.

Long-term surveillance: All patients require ongoing echocardiographic follow-up to detect residual shunt, monitor device integrity, assess right heart regression, and track pulmonary artery pressure in those with pre-procedure PAH.

Structured post-procedure follow-up is essential to optimise long-term outcomes and detect rare late complications.

Antiplatelet therapy — device closure: Current ACC/AHA and ESC guidelines recommend dual antiplatelet therapy — aspirin 75–100 mg/day plus clopidogrel 75 mg/day — for 6 months following device implantation. This supports safe endothelialisation and prevents device thrombus. Aspirin monotherapy (75–100 mg/day) continues for a further 6 months (total 12 months of antiplatelet coverage). Patients with concurrent atrial fibrillation may require anticoagulation instead of antiplatelet therapy, guided by CHA₂DS₂-VASc score.

Infective endocarditis (IE) prophylaxis: The ESC 2023 IE Prevention Guidelines recommend prophylaxis for invasive dental procedures for 6 months post-device implantation. After confirmed complete closure at the 6-month echocardiogram, routine IE prophylaxis for dental procedures is no longer required in the absence of other risk factors. Patients with any persistent residual para-device shunt continue prophylaxis indefinitely.

Echocardiographic surveillance schedule:

• 1 month post-procedure: Device position and integrity, colour Doppler for residual shunt, early right ventricular size assessment.
• 6 months: Confirmation of complete closure, right heart regression, pulmonary artery pressure estimation by tricuspid regurgitation velocity.
• 12 months: Final verification of right heart normalisation, long-term device assessment.
• Annual surveillance (long-term): Recommended for patients with prior PAH, defects closed after age 40, or incomplete right heart regression at 12 months.

Activity restrictions — device closure: High-contact sports and chest-trauma-risk activities are restricted for 6 months post-implantation to reduce erosion risk during the endothelialisation phase. After confirmed complete closure at 6-month echo, unrestricted activity is permitted.

Post-surgical follow-up: Sternal precautions (no lifting >5 kg) for 6–8 weeks; wound monitoring; echocardiography at 6 weeks and 12 months post-repair. Cardiac rehabilitation is recommended for adults with pre-operative functional limitation. Long-term rhythm monitoring for patients with pre-operative atrial arrhythmias.

The total cost of ASD closure varies substantially by closure modality, device selection, institution, and country of treatment.

Western country costs: In the United States, transcatheter ASD device closure ranges from USD 30,000–60,000 (inclusive of device cost ~USD 4,000–6,000 for the ASO, catheterisation laboratory fees, anaesthesia, and 1–2 day hospitalisation). Open surgical repair costs USD 45,000–80,000 with a 5–7 day inpatient stay. In the United Kingdom (private, self-pay), device closure costs approximately GBP 18,000–25,000; surgical repair GBP 20,000–30,000.

Medical tourism pricing (2025–2026 estimates):

• India (NABH/JCI centres — Apollo, Fortis, Narayana Health, AIIMS): Device closure USD 4,000–7,000; surgical repair USD 5,000–9,000. India has exceptionally experienced paediatric and adult congenital cardiac surgery programmes with internationally trained specialists.
• Thailand (Bumrungrad, Bangkok Heart Hospital): Device closure USD 8,000–12,000; surgical repair USD 10,000–15,000.
• Turkey (Anadolu Medical, Memorial, Acıbadem): Device closure USD 5,000–9,000.
• Malaysia (Pantai, Gleneagles, IJN — National Heart Institute): Device closure USD 7,000–11,000.
• Singapore (National Heart Centre, Mount Elizabeth): Device closure USD 12,000–18,000.

Key cost determinants:

• Device type and diameter (larger devices and newer-generation designs carry higher cost)
• ICE guidance versus TEE (ICE avoids general anaesthesia but adds USD 1,500–3,000 to procedure cost)
• Haemodynamic catheterisation for PVR assessment in PAH patients
• Length of hospital stay and HDU or ICU utilisation
• Surgeon and centre experience level
• Post-procedure echocardiographic surveillance costs
• Travel, accommodation, and interpreter services for international patients

Most health insurance plans in Western countries cover ASD closure as medically necessary when Qp:Qs >1.5:1 and right heart enlargement are documented. Pre-authorisation with echocardiographic evidence of haemodynamic significance is typically required.

For patients with small haemodynamically insignificant ASDs, those declining intervention, or those in whom closure is contraindicated, the following strategies are employed:

Watchful waiting with annual surveillance: Small ostium secundum ASDs with Qp:Qs <1.5:1, no right heart enlargement, no symptoms, and no embolic history do not require closure. Annual TTE detects interval change in shunt fraction and right ventricular dimensions. A proportion of small defects (<8 mm) close spontaneously in early childhood.

Medical management of secondary complications:

• Atrial arrhythmias: Rate control (beta-blockers, digoxin), rhythm control (antiarrhythmics, catheter ablation for AF/flutter), and anticoagulation per CHA₂DS₂-VASc score.
• Right heart failure: Furosemide, spironolactone, fluid restriction, and optimisation of systemic comorbidities.
• Paradoxical embolism risk in sinus rhythm: Aspirin 75–100 mg/day while planning definitive closure.

Oral anticoagulation for PFO — alternative to device closure: In cryptogenic stroke patients over 60, or those declining device closure, direct oral anticoagulants (apixaban, rivaroxaban) are preferred over antiplatelet monotherapy. However, the CLOSE and REDUCE trials demonstrated superiority of device closure over anticoagulation in patients under 60 with high-risk PFO anatomy (large PFO or atrial septal aneurysm).

Pulmonary vasodilator therapy in Eisenmenger syndrome: When irreversible PAH and net right-to-left shunting preclude ASD closure, PAH-targeted therapy — endothelin receptor antagonists (bosentan, macitentan), PDE-5 inhibitors (sildenafil, tadalafil), and prostacyclin analogues (inhaled iloprost, subcutaneous treprostinil) — improves functional class and 6-minute walk distance without addressing the underlying structural defect.

Emerging transcatheter approaches: Catheter-based suture-plication devices for defects with inadequate rims, and biodegradable occluders, are under clinical investigation. Concurrent left atrial appendage occlusion during ASD/PFO closure is being evaluated for patients with coexisting non-valvular AF.